TY - JOUR
T1 - Mechanism responsible for the salutary effects of flutamide on cardiac performance after trauma-hemorrhagic shock
T2 - Upregulation of cardiomyocyte estrogen receptors
AU - Yu, Huang Ping
AU - Yang, Shaolong
AU - Choudhry, Mashkoor A.
AU - Hsieh, Ya Ching
AU - Bland, Kirby I.
AU - Chaudry, Irshad H.
PY - 2005/7
Y1 - 2005/7
N2 - Background. Although flutamide (FTM), an androgen-receptor antagonist, normalizes the depressed immune and cardiac function in males after trauma hemorrhage (T-H), the mechanism responsible for its salutary effects remains unknown. We hypothesized that the salutary effects of FTM are mediated via upregulation of estrogen receptors (ERs). Methods. Male Sprague-Dawley rats underwent T-H (laparotomy and 90 minutes of hemorrhage (35-40 mm Hg) and then resuscitated with 4x the volume of shed blood in the form of Ringer's lactate). FTM (25 mg/kg) or vehicle (propanediol) was injected subcutaneously 30 minutes before the end of resuscitation. At 2 hours after T-H or sham operation, cardiac output, stroke volume, heart rate, mean arterial pressure, ± dp/dt, and total peripheral resistance were measured (n = 6 rats per group). Immediately after the measurement of cardiac function, cardiomyocytes were isolated, RNA was extracted, and expression of ER-α, ER-β, and androgen-receptor (AR) mRNA in cardiomyocytes was determined by quantitative real-time polymerase chain reaction. ER-α, ER-β, and AR protein levels in cardiomyocytes were also measured by Western blot analysis. Results. The depressed cardiac output, stroke volume, and ± dp/dt after T-H were significantly improved in the FTM-treated T-H group. Moreover, the decrease in expression of ER-α and ER-β mRNA and protein in cardiomyocytes in the T-H group was prevented with FTM treatment after T-H. However, expression of cardiomyocytes AR mRNA and protein were not significantly different between the T-H or sham group with or without FTM treatment. Conclusions. These findings collectively suggest that, in addition to blockade of androgen receptors, flutamide-mediated ER upregulation is likely to play a role in mediating the salutary effect of flutamide on cardiac function after trauma hemorrhage.
AB - Background. Although flutamide (FTM), an androgen-receptor antagonist, normalizes the depressed immune and cardiac function in males after trauma hemorrhage (T-H), the mechanism responsible for its salutary effects remains unknown. We hypothesized that the salutary effects of FTM are mediated via upregulation of estrogen receptors (ERs). Methods. Male Sprague-Dawley rats underwent T-H (laparotomy and 90 minutes of hemorrhage (35-40 mm Hg) and then resuscitated with 4x the volume of shed blood in the form of Ringer's lactate). FTM (25 mg/kg) or vehicle (propanediol) was injected subcutaneously 30 minutes before the end of resuscitation. At 2 hours after T-H or sham operation, cardiac output, stroke volume, heart rate, mean arterial pressure, ± dp/dt, and total peripheral resistance were measured (n = 6 rats per group). Immediately after the measurement of cardiac function, cardiomyocytes were isolated, RNA was extracted, and expression of ER-α, ER-β, and androgen-receptor (AR) mRNA in cardiomyocytes was determined by quantitative real-time polymerase chain reaction. ER-α, ER-β, and AR protein levels in cardiomyocytes were also measured by Western blot analysis. Results. The depressed cardiac output, stroke volume, and ± dp/dt after T-H were significantly improved in the FTM-treated T-H group. Moreover, the decrease in expression of ER-α and ER-β mRNA and protein in cardiomyocytes in the T-H group was prevented with FTM treatment after T-H. However, expression of cardiomyocytes AR mRNA and protein were not significantly different between the T-H or sham group with or without FTM treatment. Conclusions. These findings collectively suggest that, in addition to blockade of androgen receptors, flutamide-mediated ER upregulation is likely to play a role in mediating the salutary effect of flutamide on cardiac function after trauma hemorrhage.
UR - http://www.scopus.com/inward/record.url?scp=21644463596&partnerID=8YFLogxK
U2 - 10.1016/j.surg.2005.03.006
DO - 10.1016/j.surg.2005.03.006
M3 - 文章
C2 - 16003321
AN - SCOPUS:21644463596
SN - 0039-6060
VL - 138
SP - 85
EP - 92
JO - Surgery (United States)
JF - Surgery (United States)
IS - 1
ER -